Actuate Therapeutics receives US patent allowance for elraglusib oral tablets
ACTU•Actuate Therapeutics received a U.S. patent notice of allowance covering oral elraglusib tablets. A Phase 1/2 trial planned for the first quarter of 2027 will assess the tablets in advanced cancer.
1. Patent and trial plans
Actuate Therapeutics received a U.S. patent notice of allowance covering oral elraglusib tablets, strengthening protection for its lead investigational cancer drug. A Phase 1/2 trial planned for the first quarter of 2027 will assess safety, tolerability and preliminary antitumor activity in advanced cancer.
2. Tablet design
The daily tablet is designed to sustain drug exposure and GSK-3β inhibition, potentially enhancing antitumor immune responses. Preclinical and clinical exposure analyses identified plasma thresholds associated with clinical benefit, tumor growth inhibition and reduced tumor size.
